PolyPid (PYPD) Retained Earnings (2019 - 2026)
PolyPid (PYPD) posted Retained Earnings of -$309.2 million for Q1 2026, down 2.56% sequentially from -$301.5 million in Q4 2025, and down 12.2% YoY from -$352.2 million in Q1 2025.
PolyPid (PYPD) Retained Earnings (2019 - 2026) Analysis & Trends
PolyPid has reported Retained Earnings for 8 years, with the latest figure at -$309.2 million in Q1 2026.
- Quarterly Retained Earnings fell 12.2% year-over-year to -$309.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$309.2 million (down 12.2% YoY) and the FY2025 annual result came in at -$301.5 million, down 12.78% from the prior year.
- Retained Earnings eased to -$309.2 million in Q1 2026 per PYPD's latest filing, from -$301.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $220.3 million in Q4 2022 and troughed at -$309.2 million in Q1 2026.
- A 5-year average of -$222.2 million and a median of -$244.8 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings increased 4.47% in 2022, then tumbled 208.19% in 2023.
- Over 5 years, Retained Earnings stood at $220.3 million in 2022, then sank by 208.19% to -$238.3 million in 2023, then declined by 12.18% to -$267.3 million in 2024, then slipped by 12.78% to -$301.5 million in 2025, then declined by 2.56% to -$309.2 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$309.2 million, -$301.5 million, and -$293.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | -317.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -317.08 Mn |
| Mar 31, 2026 | -309.23 Mn |
| Dec 31, 2025 | -301.50 Mn |
| Sep 30, 2025 | -293.03 Mn |
| Jun 30, 2025 | -285.58 Mn |
| Mar 31, 2025 | -275.60 Mn |
| Dec 31, 2024 | -267.33 Mn |
| Sep 30, 2024 | -258.81 Mn |
| Jun 30, 2024 | -251.05 Mn |
| Mar 31, 2024 | -244.76 Mn |
| Dec 31, 2023 | -238.31 Mn |
| Sep 30, 2023 | -231.95 Mn |
| Jun 30, 2023 | -226.35 Mn |
| Mar 31, 2023 | -220.51 Mn |
| Dec 31, 2022 | 220.27 Mn |
| Sep 30, 2022 | -207.88 Mn |
| Jun 30, 2022 | -198.61 Mn |
| Mar 31, 2022 | -186.76 Mn |
| Dec 31, 2021 | 210.85 Mn |
| Sep 30, 2021 | -161.39 Mn |